Adarza BioSystems, a West Henrietta, NY- and St. Peters, MO-based provider of label-free, multiplex assays, closed a $5m Series B financing.
Backers included Cultivation Capital, Lewis and Clark Ventures and Siemens’ venture capital arm.
The company intends to use the funds to expand production capacity in its MO manufacturing facility and launch its first immunoassay product consumable and instrument platform, to accelerate development of assays targeting a variety of biological analytes including cytokines, antigens and small molecules.
Founded in 2008 and led by Rand Henke, Ph.D., CEO, Adarza provides the Arrayed Imaging Reflectometry (AIR™), a label-free platform technology that enables the simultaneous detection of hundreds of analytes in a single drop of fluid, this enabling multiplexed protein detection with high sensitivity and specificity. The company’s technology addresses broad quantitative analyte detection applications, including cancer biomarkers, drug and vaccine development, allergy, immunology and infectious diseases research.